Can Hypothermia be Incorporated Into Primary Angioplasty for Heart Attack? (CHIPAHA)
ST-Elevation Myocardial Infarction
Device: Life Recovery Systems ThermoSuit
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Can Hypothermia be Incorporated Into Primary Angioplasty for Heart Attack?|
- Feasibility of use of cooling device as determined by ability and time to achieve target temperature and ease of maintaining temperature in therapeutic range (32 to 34°C) for three hours following removal of patient from ThermoSuit. [ Time Frame: Four hours ] [ Designated as safety issue: No ]
- Primary safety endpoint: composite of serious adverse events including: death, re-infarction, ischemia-driven TVR, pneumonia, sepsis, arrhythmia, bleeding, stroke, and renal failure. [ Time Frame: 30 days post-hospital discharge ] [ Designated as safety issue: Yes ]
- Major adverse cardiac events at 30 days as defined by death or non-fatal re-infarction. c. Ischemia-driven target vessel revascularization. [ Time Frame: 30 days post-hospital discharge ] [ Designated as safety issue: Yes ]
- Myocardial infarct size at 30 days as measured by 99mTc-sestamibi SPECT imaging. [ Time Frame: 30 days post-hospital discharge ] [ Designated as safety issue: Yes ]
- Safety, including all-cause mortality, cardiac, vascular, and hematological complications. [ Time Frame: 30 days post-hospital discharge ] [ Designated as safety issue: Yes ]
- Adverse events associated with conscious sedation. [ Time Frame: 30 days post-hospital discharge ] [ Designated as safety issue: Yes ]
- Arterial blood pressure and heart rate every 5 minutes from the baseline just before the start of cooling until 30 minutes after cooling has started. [ Time Frame: One hour ] [ Designated as safety issue: Yes ]
- Door to balloon time. [ Time Frame: 90 minutes ] [ Designated as safety issue: Yes ]
|Study Start Date:||February 2016|
|Estimated Study Completion Date:||February 2018|
|Estimated Primary Completion Date:||December 2017 (Final data collection date for primary outcome measure)|
Experimental: ThermoSuit-Induced Patient Cooling
The Life Recovery Systems ThermoSuit System will be used to cool STEMI patients under conditions of conscious sedation.
Device: Life Recovery Systems ThermoSuit
Hypothermia induction (cooling to 32 to 34 degrees C core temperature) using the Life Recovery Systems ThermoSuit System (a device which cools patients using direct skin contact with cold water) followed by PCI (percutaneous coronary intervention) and maintenance of hypothermia for 3 hours following PCI.
Other Name: Life Recovery Systems ThermoSuit(R) System
This clinical study will investigate the safety and feasibility of cooling heart attack (STEMI) patients with the LRS (Life Recovery Systems)ThermoSuit System, a cooling device which uses the principle of cold water immersion to rapidly reduce patient temperature. The study will enroll a total of up to 20 patients, and will be a cooperative effort between LRS and LSU Health Sciences Center - Shreveport.
The study is being conducted under an IDE (Investigational Device Exemption) that was granted to LRS by FDA (G070141). The primary goal of this trial is to demonstrate the feasibility of cooling AMI patients pre-reperfusion with the ThermoSuit cooling device. The safety of this treatment will be determined by review of a composite of serious adverse events.
Consciously sedated patients will be cooled after entry into the emergency room and prior to percutaneous coronary intervention in the catheterization laboratory. It is hypothesized that the ThermoSuit System will enable cooling of the patient to 34ºC after a treatment of 30 minutes or less. Previous research has suggested that cooling of ST-elevation myocardial infarction patients before coronary reperfusion could result in a significant reduction in myocardial infarct size.
If successful, this study will lead to a pivotal clinical study to investigate the potential for the ThermoSuit cooling treatment to reduce myocardial infarct size. The ultimate goal of these studies is to determine the safety and effectiveness of the use of the ThermoSuit device for the treatment of AMI patients.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00763828
|Contact: Robert B Schock, Ph.D.||firstname.lastname@example.org|
|Contact: Rick Hettenbach, MAemail@example.com|
|United States, Texas|
|UTHSCSA||Not yet recruiting|
|San Antonio, Texas, United States, 78229-3900|
|Contact: Steven R Bailey, MD 210-567-3885 BailyS@uthscsa.edu|
|Contact: Joan Drake, RN, BSN, MPH 210-567-8692 DrakeP@uthscsa.edu|
|Study Chair:||Robert J Freedman, M.D.||Life Recovery Systems|